secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001628280-25-036843
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M
-----------------------------------------------------------------

- Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).
- Net loss $27.2M (diluted EPS -$0.46) vs. net loss $4.5M (-$0.08) in Q2 2024.
- Cash $325.6M, down $15.4M from Q1 2025; full-year revenue guidance reaffirmed $210-250M.
- Regulatory milestones: Bysanti NDA PDUFA Feb 21, 2026; Tradipitant NDA PDUFA Dec 30, 2025; Imsidolimab BLA submission expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/0001628280-25-036843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer